What is the updated (2023–2024 Formula) COVID-19 vaccination schedule for moderately or severely immunocompromised people?

Please see the CDC interim COVID-19 vaccination schedule for each vaccine for immunocompromised people in each eligible age group: www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf or, for additional details, see CDC’s Interim Clinical Considerations for the Use of COVID-19 Vaccines for dosage guidance: www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#immunocompromised.

People who are moderately or severely immunocompromised, who have not been vaccinated against COVID-19 in the past, and who are receiving the 2023–2024 Formula Novavax COVID-19 Vaccine should receive 2 doses spaced 3 to 8 weeks apart. They may receive a third dose at least 2 months after dose 2. As with mRNA COVID-19 vaccine recipients, they may receive additional doses at the discretion of their healthcare provider, based on their individual circumstances. CDC recommends that any additional doses be administered at least 2 months after the most recent 2023–2024 Formula dose.

Immunocompromised people should be counseled that they may have a reduced immune response to COVID-19 vaccination. They should be advised to continue other recommended infection prevention measures, such as wearing a face mask and avoiding crowds, to limit their risk of exposure to the SARS-CoV-2 virus.